- Jan 05 2018
PDS bolsters patent portfolio with new patent
PDS Biotechnology Bolsters its Patent Portfolio with New Patent Addressing Mechanism of Action of Novel Versamune Immunotherapeutic via Activation of the Type I Interferon Pathway
North Brunswick, NJ—PDS Biotechnology Corporation, a clinical-stage immuno-oncology company pioneering the development of novel multifunctional immunotherapeutic products, announced today that it has filed a patent covering use of the Versamune® technology platform to activate a critical immunological signaling pathway known as the Type I Interferon pathway.
Stimulation of Interferon Genes (STING) has been identified as a primary mediator of innate immunity, and induces the expression of type I interferons, cytokines, and T-cell recruiting chemokines, resulting in the activation of antigen-presenting cells, effector cells, such as natural killer (NK) cells, and disease-targeting T-cells. Stimulation of Interferon Genes is recognized as a significant potential mechanism of action in the fight to kill potential cancer tumor cells.
Interferons have been determined to play a multifaceted role in the induction of antitumor immunity. Interferons have direct cytotoxic effects on tumors, promote maturation and antigen presentation of DCs, and boost CD8+ T cell-mediated antitumor immune responses.
PDS Biotechnology’s research and development program, which is focused on the application of cationic lipids to the development of superior cancer immunotherapies, has identified that certain structurally specific cationic lipids act as potent activators of Type I Interferon genes and associated CD8+ T-cell activating chemokines. PDS has now demonstrated that such lipids are able to generate high levels of potent and targeted anti-tumor polyfunctional CD8+ T-cell responses via activation of the interferon pathway, resulting in superior anti-tumor efficacy. The induction of strong antigen-specific CD8+ T-cell responses has also been recently confirmed in a PDS-sponsored Phase 1/2a human clinical trial.
Versamune® is a novel clinical stage, synthetic lipid-based immunotherapy platform. The Versamune®-based products which are administered by sub-cutaneous injection, have been demonstrated to facilitate superior anti-tumor efficacy due to the platform’s multi-functional mechanism of action. The platform provides potent activation of the type I interferon genes. The mechanism of action also involves effective presentation of the tumor antigens via the MHC Class I pathway. Both mechanisms together promote strong in-vivo induction of polyfunctional tumor-targeting CD8+ T-cells. This result, as well as excellent safety were confirmed in a Phase 1/2a human clinical trial. The Versamune® approach also inhibits immune-suppressive regulatory T-cells within the tumors, further facilitating the anti-tumor efficacy of the products. The Versamune® platform is now being applied to the development of multiple Phase 2b clinical-stage cancer products, including both early and late-stage cancer indications, as well as combinations with other successful immuno-oncology approaches such as checkpoint inhibitors.
About PDS Biotechnology
PDS Biotechnology is a private biopharmaceutical company with a growing pipeline of simpler, safer, and more effective clinical-stage immunotherapies to treat various early-stage and late-stage cancers. PDS is progressing a pipeline of immuno-oncology products to treat various cancers including, head and neck cancer, cervical cancer, prostate cancer, breast cancer etc. into phase 2 human clinical trials. This pipeline progression is based on successful demonstration of safety, and strong induction of antigen-specific CD8+ T-cell responses in a recently completed phase 1/2a human clinical trial.